{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:26:16Z","timestamp":1793949976894,"version":"4.8.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":82,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400234"],"award-info":[{"award-number":["82400234"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01553-4","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:28:31Z","timestamp":1782912511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-1667","authenticated-orcid":false,"given":"Qunling","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8450-7583","authenticated-orcid":false,"given":"Shiyu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longlong","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1320-7364","authenticated-orcid":false,"given":"Yizhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanxu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5766-1625","authenticated-orcid":false,"given":"Rong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5999-7237","authenticated-orcid":false,"given":"Xiaoyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3146-9413","authenticated-orcid":false,"given":"Junning","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"1553_CR1","first-page":"443","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66:443\u201359.","journal-title":"CA Cancer J Clin"},{"key":"1553_CR2","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.18632\/aging.204006","volume":"14","author":"W Liu","year":"2022","unstructured":"Liu W, Liu J, Song Y, Wang X, Mi L, Cai C, et al. Burden of lymphoma in China, 1990-2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019. Aging (Albany NY). 2022;14:3175\u201390.","journal-title":"Aging (Albany NY)"},{"key":"1553_CR3","unstructured":"Li X, Li G, Gao Z, Zhou X, Zhu X, editors. The relative frequencies of lymphoma subtypes in China: a nationwide study of 10002 cases by the Chinese Lymphoma Study Group. Annals of Oncology; 2011: OXFORD UNIV PRESS GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND."},{"key":"1553_CR4","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010;116:2040\u20135.","journal-title":"Blood"},{"key":"1553_CR5","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013\u201322.","journal-title":"Lancet Oncol"},{"key":"1553_CR6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","volume":"2016","author":"B Coiffier","year":"2016","unstructured":"Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematol Am Soc Hematol Educ Program. 2016;2016:366\u201378.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"1553_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u201342.","journal-title":"N Engl J Med"},{"key":"1553_CR8","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","volume":"384","author":"LH Sehn","year":"2021","unstructured":"Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384:842\u201358.","journal-title":"N Engl J Med"},{"key":"1553_CR9","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1182\/blood-2015-05-647602","volume":"126","author":"C Copie-Bergman","year":"2015","unstructured":"Copie-Bergman C, Cuilliere-Dartigues P, Baia M, Briere J, Delarue R, Canioni D, et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA\/LYSA study. Blood. 2015;126:2466\u201374.","journal-title":"Blood"},{"key":"1553_CR10","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1200\/JCO.19.00743","volume":"37","author":"A Rosenwald","year":"2019","unstructured":"Rosenwald A, Bens S, Advani R, Barrans S, Copie-Bergman C, Elsensohn MH, et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the lunenburg lymphoma biomarker consortium. J Clin Oncol. 2019;37:3359\u201368.","journal-title":"J Clin Oncol"},{"key":"1553_CR11","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1182\/blood-2016-11-747022","volume":"129","author":"D Ennishi","year":"2017","unstructured":"Ennishi D, Mottok A, Ben-Neriah S, Shulha HP, Farinha P, Chan FC, et al. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood. 2017;129:2760\u201370.","journal-title":"Blood"},{"key":"1553_CR12","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 2020;135:1759\u201371.","journal-title":"Blood"},{"key":"1553_CR13","doi-asserted-by":"publisher","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","volume":"120","author":"ZY Xu-Monette","year":"2012","unstructured":"Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012;120:3986\u201396.","journal-title":"Blood"},{"key":"1553_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386:351\u201363.","journal-title":"N Engl J Med"},{"key":"1553_CR15","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","volume":"23","author":"MS Czuczman","year":"2017","unstructured":"Czuczman MS, Trneny M, Davies A, Rule S, Linton KM, Wagner-Johnston N, et al. A Phase 2\/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator\u2019s Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Clin Cancer Res. 2017;23:4127\u201337.","journal-title":"Clin Cancer Res"},{"key":"1553_CR16","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med. 2015;21:922\u20136.","journal-title":"Nat Med"},{"key":"1553_CR17","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma. J Clin Oncol. 2017;35:826\u201333.","journal-title":"J Clin Oncol"},{"key":"1553_CR18","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1200\/JCO.20.01366","volume":"39","author":"GS Nowakowski","year":"2021","unstructured":"Nowakowski GS, Chiappella A, Gascoyne RD, Scott DW, Zhang Q, Jurczak W, et al. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2021;39:1317\u201328.","journal-title":"J Clin Oncol"},{"key":"1553_CR19","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.18.02403","volume":"37","author":"A Younes","year":"2019","unstructured":"Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-Cell Lymphoma. J Clin Oncol. 2019;37:1285\u201395.","journal-title":"J Clin Oncol"},{"key":"1553_CR20","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","volume":"15","author":"A Younes","year":"2014","unstructured":"Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014;15:1019\u201326.","journal-title":"Lancet Oncol"},{"key":"1553_CR21","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1182\/blood.2025028649","volume":"146","author":"PP Xu","year":"2025","unstructured":"Xu PP, Zhu Y, Shi ZY, Wang L, Cheng S, Qian Y, et al. A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma. Blood. 2025;146:2561\u201373.","journal-title":"Blood"},{"key":"1553_CR22","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"1553_CR23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD, Coulibaly ZA, Roulland S, Young RM, et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell. 2020;37:551\u201368.e14.","journal-title":"Cancer Cell"},{"key":"1553_CR24","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nature22353","volume":"546","author":"G Varano","year":"2017","unstructured":"Varano G, Raffel S, Sormani M, Zanardi F, Lonardi S, Zasada C, et al. The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3beta inhibition. Nature. 2017;546:302\u20136.","journal-title":"Nature"},{"key":"1553_CR25","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1182\/bloodadvances.2022009389","volume":"7","author":"PWM Johnson","year":"2023","unstructured":"Johnson PWM, Balasubramanian S, Hodkinson B, Shreeve SM, Sun S, Srinivasan S, et al. Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL coexpressing BCL2 and MYC in the phase 3 PHOENIX trial. Blood Adv. 2023;7:2008\u201317.","journal-title":"Blood Adv"},{"key":"1553_CR26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/nan.12259","volume":"42","author":"T Nakamura","year":"2016","unstructured":"Nakamura T, Tateishi K, Niwa T, Matsushita Y, Tamura K, Kinoshita M, et al. Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol Appl Neurobiol. 2016;42:279\u201390.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"1553_CR27","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","volume":"7","author":"C Grommes","year":"2017","unstructured":"Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, et al. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discov. 2017;7:1018\u201329.","journal-title":"Cancer Discov"},{"key":"1553_CR28","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","volume":"35","author":"C Grommes","year":"2017","unstructured":"Grommes C, DeAngelis LM. Primary CNS Lymphoma. J Clin Oncol. 2017;35:2410\u20138.","journal-title":"J Clin Oncol"},{"key":"1553_CR29","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","volume":"31","author":"MS Lionakis","year":"2017","unstructured":"Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, et al. Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma. Cancer Cell. 2017;31:833\u201343.e5.","journal-title":"Cancer Cell"},{"key":"1553_CR30","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390.","journal-title":"Nat Med"},{"key":"1553_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1219167","volume":"14","author":"H Geng","year":"2023","unstructured":"Geng H, Jia S, Zhang Y, Li J, Yang Q, Zeng L, et al. Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement. Front Immunol. 2023;14:1219167.","journal-title":"Front Immunol"},{"key":"1553_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35697","volume":"131","author":"X Yin","year":"2025","unstructured":"Yin X, He Q, Liu D, Xie L, Wang H, Chen C, et al. Zanubrutinib plus R-CHOP for the treatment of newly diagnosed double-expressor lymphoma: A phase 2 clinical study. Cancer. 2025;131:e35697.","journal-title":"Cancer"},{"key":"1553_CR33","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201368.","journal-title":"J Clin Oncol"},{"key":"1553_CR34","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211072839","volume":"13","author":"R Chen","year":"2022","unstructured":"Chen R, Zhou D, Wang L, Zhu L, Ye X. MYD88(L265P) and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy. Ther Adv Hematol. 2022;13:20406207211072839.","journal-title":"Ther Adv Hematol"},{"key":"1553_CR35","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3324\/haematol.2018.214122","volume":"105","author":"JS Vermaat","year":"2020","unstructured":"Vermaat JS, Somers SF, de Wreede LC, Kraan W, de Groen RAL, Schrader AMR, et al. MYD88 mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis. Haematologica. 2020;105:424\u201334.","journal-title":"Haematologica"},{"key":"1553_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7005","volume":"13","author":"T Deng","year":"2024","unstructured":"Deng T, Zhang S, Xiao M, Gu J, Huang L, Zhou X. A single-centre, real-world study of BTK inhibitors for the initial treatment of MYD88(mut) \/CD79B(mut) diffuse large B-cell lymphoma. Cancer Med. 2024;13:e7005.","journal-title":"Cancer Med"},{"key":"1553_CR37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00262-025-04090-4","volume":"74","author":"X Xiao","year":"2025","unstructured":"Xiao X, Yuan S, Chen X, Liu X, Zhao R, Zhao S, et al. Favorable impact of zanubrutinib combined with R-CHOP regimen in MYD88-mutated new-diagnosed diffuse large B-cell lymphoma: a retrospective study with propensity score-matched analysis. Cancer Immunol Immunother. 2025;74:259.","journal-title":"Cancer Immunol Immunother"},{"key":"1553_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55614-y","volume":"16","author":"MS Mendeville","year":"2025","unstructured":"Mendeville MS, Janssen J, Los-de Vries GT, van Dijk E, Richter J, Nijland M, et al. Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphoma. Nat Commun. 2025;16:109.","journal-title":"Nat Commun"}],"updated-by":[{"DOI":"10.1038\/s41408-026-01642-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:00:00Z","timestamp":1793836800000}}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01553-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01553-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01553-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:38:50Z","timestamp":1793947130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01553-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1553"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01553-4","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"1 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: During the proof stage, we noticed that Figure 2B had been incorrectly compiled\u2014it displayed the CR rate instead of the OR rate. We therefore made a correction to Figure 2 (specifically, we replaced Figure 2B with the correct panel).","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2026","order":10,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":11,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41408-026-01642-4","URL":"https:\/\/doi.org\/10.1038\/s41408-026-01642-4","order":13,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All authors approved the final manuscript and the submission to this journal.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The present study was designed and conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent before enrollment. This study was registered with ClinicalTrials.gov, number NCT05290337.","order":3,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"159"}}